{"success":true,"data":{"pressRelease":{"id":"114010","rtpr_id":"nGNX7tF6Xk","ticker":"WVE","exchange":"NASDAQ","all_tickers":["WVE"],"title":"Wave Life Sciences Announces Completion of Redomiciliation to Delaware","author":"Globe Newswire","published_at":"2026-08-10T12:30:00.048Z","article_body":"CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc.\n(NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the\nbroad potential of RNA medicines to transform human health (“Wave” or\n“Wave Life Sciences”), today announced the completion of the\nredomiciliation process to change the parent company of the Wave group of\ncompanies from a Singapore company to a Delaware corporation by way of a\nstatutory procedure known as a scheme of arrangement under Section 210 of the\nCompanies Act 1967 of Singapore (the “Redomiciliation”).\n\nThe Redomiciliation was completed after the close of trading on Friday, August\n7, 2026 (Eastern Time), at which time all issued ordinary shares of Wave Life\nSciences Ltd. were exchanged on a one-for-one basis for newly issued shares of\ncommon stock of Wave Life Sciences, Inc., a Delaware corporation. Wave’s\nequity will continue to trade under the trading symbol of “WVE” and its\nnewly issued common stock will begin trading on the NASDAQ on Monday, August\n10, 2026. Wave does not anticipate any material impact to its employees or its\nday-to-day business as a result of the completion of the Redomiciliation.\n\nAbout Wave Life Sciences\n\nWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on\nunlocking the broad potential of RNA medicines to transform human health.\nWave’s RNA medicines platform, PRISM(®), combines multiple modalities,\nchemistry innovation, and deep insights in human genetics to deliver\nscientific breakthroughs that treat both rare and common disorders. Its\ntoolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing\n(AIMers), provides Wave with unmatched capabilities for designing and\nsustainably delivering candidates that optimally address disease biology.\nWave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin\ndeficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and\nalso includes clinical programs in Duchenne muscular dystrophy and\nHuntington’s disease, as well as several preclinical programs utilizing the\ncompany’s versatile RNA medicines platform. Driven by the calling to\n“Reimagine Possible,” Wave is leading the charge toward a world in which\nhuman potential is no longer hindered by the burden of disease. Wave is\nheadquartered in Cambridge, MA. For more information on Wave’s science,\npipeline and people, please visit www.wavelifesciences.com and follow Wave on\nX and LinkedIn.\n\nCautionary Note Regarding Forward-Looking Statements\n\nSome of the statements included in this announcement may include\n“forward-looking statements” within the meaning of the Private Securities\nLitigation Reform Act of 1995, in particular, statements about our\nexpectations regarding the change of the parent company of the group from a\nSingapore company to a Delaware corporation. These statements include, but are\nnot limited to, statements that address our expected future business and\nstatements about the Redomiciliation and other statements identified by words\nsuch as “will”, “expect”, “believe”, “anticipate”,\n“estimate”, “should”, “intend”, “plan”, “potential”,\n“predict”, “project”, “aim”, and similar words, phrases or\nexpressions. These forward-looking statements are based on current\nexpectations and beliefs of the management of Wave Life Sciences, as well as\nassumptions made by, and information currently available to, such management,\ncurrent market trends and market conditions and involve risks and\nuncertainties, many of which are outside Wave Life Sciences’ and\nmanagement’s control, and which may cause actual results to differ\nmaterially from those contained in forward looking statements. Accordingly,\nyou should not place undue reliance on such statements.\n\nParticular uncertainties that could materially affect future results include\nrisks associated with the Redomiciliation; our ability to realize the expected\nbenefits from the Redomiciliation; the occurrence of difficulties or material\ntiming delays in connection with the Redomiciliation, including any\nunanticipated costs in connection therewith; any delays, challenges and\nexpenses associated with receiving governmental and regulatory approvals;\nchanges in tax laws, tax treaties or tax regulations or the interpretation or\nenforcement thereof by the tax authorities in Singapore, the United States and\nother jurisdictions following the Redomiciliation; our critical accounting\npolicies; the ability of our preclinical studies to produce data sufficient\nto support the filing of global clinical trial applications and the timing\nthereof; our ability to continue to build and maintain the company\ninfrastructure and personnel needed to achieve our goals; the clinical\nresults and timing of our programs, which may not support further development\nof our product candidates; actions of regulatory agencies, which may affect\nthe initiation, timing and progress of clinical trials; our effectiveness in\nmanaging current and future clinical trials and regulatory processes; the\nsuccess of our platform in identifying viable candidates; the continued\ndevelopment and acceptance of nucleic acid therapeutics as a class of drugs;\nour ability to demonstrate the therapeutic benefits of our stereopure\ncandidates in clinical trials, including our ability to develop candidates\nacross multiple therapeutic modalities; our ability to obtain, maintain and\nprotect intellectual property; our ability to enforce our patents against\ninfringers and defend our patent portfolio against challenges from third\nparties; our ability to fund our operations and to raise additional capital\nas needed; competition from others developing therapies for similar uses;\nand any impacts on our business as a result of or related to any local and\nglobal health epidemics, geopolitical conflicts, global economic uncertainty,\nthe impact of tariffs and changes in economic policies, volatility in\ninflation, volatility in interest rates or market disruptions on our business.\n\nThe foregoing review of important factors should not be construed as\nexhaustive and should be read in conjunction with the other cautionary\nstatements that are set forth in our definitive proxy statement filed on May\n7, 2026 and our most recent Annual Report on Form 10-K, Quarterly Reports on\nForm 10-Q and the other documents that we file with the SEC, including under\nthe heading “Risk Factors” in our most recent Annual Report on Form 10-K.\nYou may obtain copies of these documents as described under the heading\n“Additional Information and Where to Find It.”\n\nOur filings with the Securities and Exchange Commission (“SEC”), which you\nmay obtain without charge at the SEC’s website at http://www.sec.gov,\ndiscuss some of the important risk factors that may affect our business,\nresults of operations and financial condition. We undertake no intent or\nobligation to publicly update or revise any of these forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except as required by law.\n\nInvestors:\n\nJames Salierno\nDirector, Investor Relations\n+1 617-949-4043 \nInvestorRelations@wavelifesci.com\n\nMedia:\n\nKatie Sullivan\nSenior Director, Corporate Communications\n+1 617-949-2936\nMediaRelations@wavelifesci.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b2c5e218-8ae8-4dc2-b6f2-cf55b6b3b6e0)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7tF6Xk","title":"Wave Life Sciences Announces Completion of Redomiciliation to Delaware","author":"Globe Newswire","ticker":"WVE","created":"2026-08-10T12:30:00.048Z","tickers":["WVE"],"exchange":"NASDAQ","article_body":"CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc.\n(NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the\nbroad potential of RNA medicines to transform human health (“Wave” or\n“Wave Life Sciences”), today announced the completion of the\nredomiciliation process to change the parent company of the Wave group of\ncompanies from a Singapore company to a Delaware corporation by way of a\nstatutory procedure known as a scheme of arrangement under Section 210 of the\nCompanies Act 1967 of Singapore (the “Redomiciliation”).\n\nThe Redomiciliation was completed after the close of trading on Friday, August\n7, 2026 (Eastern Time), at which time all issued ordinary shares of Wave Life\nSciences Ltd. were exchanged on a one-for-one basis for newly issued shares of\ncommon stock of Wave Life Sciences, Inc., a Delaware corporation. Wave’s\nequity will continue to trade under the trading symbol of “WVE” and its\nnewly issued common stock will begin trading on the NASDAQ on Monday, August\n10, 2026. Wave does not anticipate any material impact to its employees or its\nday-to-day business as a result of the completion of the Redomiciliation.\n\nAbout Wave Life Sciences\n\nWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on\nunlocking the broad potential of RNA medicines to transform human health.\nWave’s RNA medicines platform, PRISM(®), combines multiple modalities,\nchemistry innovation, and deep insights in human genetics to deliver\nscientific breakthroughs that treat both rare and common disorders. Its\ntoolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing\n(AIMers), provides Wave with unmatched capabilities for designing and\nsustainably delivering candidates that optimally address disease biology.\nWave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin\ndeficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and\nalso includes clinical programs in Duchenne muscular dystrophy and\nHuntington’s disease, as well as several preclinical programs utilizing the\ncompany’s versatile RNA medicines platform. Driven by the calling to\n“Reimagine Possible,” Wave is leading the charge toward a world in which\nhuman potential is no longer hindered by the burden of disease. Wave is\nheadquartered in Cambridge, MA. For more information on Wave’s science,\npipeline and people, please visit www.wavelifesciences.com and follow Wave on\nX and LinkedIn.\n\nCautionary Note Regarding Forward-Looking Statements\n\nSome of the statements included in this announcement may include\n“forward-looking statements” within the meaning of the Private Securities\nLitigation Reform Act of 1995, in particular, statements about our\nexpectations regarding the change of the parent company of the group from a\nSingapore company to a Delaware corporation. These statements include, but are\nnot limited to, statements that address our expected future business and\nstatements about the Redomiciliation and other statements identified by words\nsuch as “will”, “expect”, “believe”, “anticipate”,\n“estimate”, “should”, “intend”, “plan”, “potential”,\n“predict”, “project”, “aim”, and similar words, phrases or\nexpressions. These forward-looking statements are based on current\nexpectations and beliefs of the management of Wave Life Sciences, as well as\nassumptions made by, and information currently available to, such management,\ncurrent market trends and market conditions and involve risks and\nuncertainties, many of which are outside Wave Life Sciences’ and\nmanagement’s control, and which may cause actual results to differ\nmaterially from those contained in forward looking statements. Accordingly,\nyou should not place undue reliance on such statements.\n\nParticular uncertainties that could materially affect future results include\nrisks associated with the Redomiciliation; our ability to realize the expected\nbenefits from the Redomiciliation; the occurrence of difficulties or material\ntiming delays in connection with the Redomiciliation, including any\nunanticipated costs in connection therewith; any delays, challenges and\nexpenses associated with receiving governmental and regulatory approvals;\nchanges in tax laws, tax treaties or tax regulations or the interpretation or\nenforcement thereof by the tax authorities in Singapore, the United States and\nother jurisdictions following the Redomiciliation; our critical accounting\npolicies; the ability of our preclinical studies to produce data sufficient\nto support the filing of global clinical trial applications and the timing\nthereof; our ability to continue to build and maintain the company\ninfrastructure and personnel needed to achieve our goals; the clinical\nresults and timing of our programs, which may not support further development\nof our product candidates; actions of regulatory agencies, which may affect\nthe initiation, timing and progress of clinical trials; our effectiveness in\nmanaging current and future clinical trials and regulatory processes; the\nsuccess of our platform in identifying viable candidates; the continued\ndevelopment and acceptance of nucleic acid therapeutics as a class of drugs;\nour ability to demonstrate the therapeutic benefits of our stereopure\ncandidates in clinical trials, including our ability to develop candidates\nacross multiple therapeutic modalities; our ability to obtain, maintain and\nprotect intellectual property; our ability to enforce our patents against\ninfringers and defend our patent portfolio against challenges from third\nparties; our ability to fund our operations and to raise additional capital\nas needed; competition from others developing therapies for similar uses;\nand any impacts on our business as a result of or related to any local and\nglobal health epidemics, geopolitical conflicts, global economic uncertainty,\nthe impact of tariffs and changes in economic policies, volatility in\ninflation, volatility in interest rates or market disruptions on our business.\n\nThe foregoing review of important factors should not be construed as\nexhaustive and should be read in conjunction with the other cautionary\nstatements that are set forth in our definitive proxy statement filed on May\n7, 2026 and our most recent Annual Report on Form 10-K, Quarterly Reports on\nForm 10-Q and the other documents that we file with the SEC, including under\nthe heading “Risk Factors” in our most recent Annual Report on Form 10-K.\nYou may obtain copies of these documents as described under the heading\n“Additional Information and Where to Find It.”\n\nOur filings with the Securities and Exchange Commission (“SEC”), which you\nmay obtain without charge at the SEC’s website at http://www.sec.gov,\ndiscuss some of the important risk factors that may affect our business,\nresults of operations and financial condition. We undertake no intent or\nobligation to publicly update or revise any of these forward-looking\nstatements, whether as a result of new information, future events or\notherwise, except as required by law.\n\nInvestors:\n\nJames Salierno\nDirector, Investor Relations\n+1 617-949-4043 \nInvestorRelations@wavelifesci.com\n\nMedia:\n\nKatie Sullivan\nSenior Director, Corporate Communications\n+1 617-949-2936\nMediaRelations@wavelifesci.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b2c5e218-8ae8-4dc2-b6f2-cf55b6b3b6e0)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-10T12:30:00.106172826Z","server_sent_at_ms":1786365000106},"received_at":"2026-08-10T12:30:00.250Z","source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341822/0/en/wave-life-sciences-announces-completion-of-redomiciliation-to-delaware.html"},"analysis":{"id":"103010","press_release_id":"114010","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Wave Life Sciences completed its redomiciliation from a Singapore company to a Delaware corporation, effective after the market close on August 7, 2026.\n\nAll issued ordinary shares were exchanged on a one-for-one basis for new common stock of the Delaware entity, with the NASDAQ ticker symbol WVE remaining unchanged.\n\nThe company stated it does not anticipate any material impact to its employees or day-to-day business operations as a result of the move.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Administrative corporate structure change; ticker and operations unchanged."},"keyFigures":{"customDimensions":{"exchange_ratio":"1-for-1"}},"quotedText":"","namedEntities":{"people":[{"name":"James Salierno","role":"Director, Investor Relations"},{"name":"Katie Sullivan","role":"Senior Director, Corporate Communications"}],"products":["WVE-007","WVE-006","WVE-008","PRISM"],"companies":[{"name":"Wave Life Sciences, Inc.","ticker":"WVE"},{"name":"Wave Life Sciences Ltd.","relationship":"pre-redomiciliation entity"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine administrative redomiciliation from Singapore to Delaware with no material change to business operations or share count (1:1 exchange)."},"tickerRelevance":{"others":[],"primary":"WVE"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"administrative","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Wave Life Sciences completed its redomiciliation from a Singapore company to a Delaware corporation, effective after the market close on August 7, 2026.\n\nAll issued ordinary shares were exchanged on a one-for-one basis for new common stock of the Delaware entity, with the NASDAQ ticker symbol WVE remaining unchanged.\n\nThe company stated it does not anticipate any material impact to its employees or day-to-day business operations as a result of the move.","key_figures":{"customDimensions":{"exchange_ratio":"1-for-1"}},"named_entities":{"people":[{"name":"James Salierno","role":"Director, Investor Relations"},{"name":"Katie Sullivan","role":"Senior Director, Corporate Communications"}],"products":["WVE-007","WVE-006","WVE-008","PRISM"],"companies":[{"name":"Wave Life Sciences, Inc.","ticker":"WVE"},{"name":"Wave Life Sciences Ltd.","relationship":"pre-redomiciliation entity"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-10T16:38:51.845Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap","eventGravity":"administrative","issuerAuthored":true}},"durationMs":336016,"modelName":"glm-4.7"}}